Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fortress Biotech Inc FBIO

Alternate Symbol(s):  FBIOP

Healthcare Biotechnology
Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops and commercializes pharmaceutical and biotechnology products and product candidates. The Company markets its various branded dermatology products, Qbrexza, Accutane, Amzeeq, Zilxi, Ximino, Exelderm and Targadox. Qbrexza (glycopyrronium 2.4%) is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis in adults and children nine years and older. Accutane (isotretinoin) is an oral capsule for the treatment of severe recalcitrant nodular acne. Amzeeq (minocycline 4%) topical foam is a topical minocycline treatment for the inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and children nine years and older. Zilxi (minocycline 1.5%) is a topical foam and a topical minocycline treatment for inflammatory lesions of rosacea in adults. Ximino (minocycline hydrochloride) is an oral minocycline drug for the treatment of moderate to severe acne.


NDAQ:FBIO - Post by User

Fortress Biotech Inc
<< Previous
 Bullboard Posts
User Avatar Image
(4)
•••
Post by AviseAnalyticson Aug 26, 2021 7:20am
186 Views
Post# 33766242

3 BIOTECH STOCKS INSIDERS ARE SELLING

3 BIOTECH STOCKS INSIDERS ARE SELLING

3 BIOTECH STOCKS INSIDERS ARE SELLING

$VERU $FBIO $SGMO

Learn More

https://www.aviseanalytics.com/3-biotech-stocks-insiders-are-selling/

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities